GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00089856
Recruitment Status : Terminated (Based on futility analysis showing <30% chance of meeting primary endpoint.)
First Posted : August 18, 2004
Last Update Posted : November 5, 2008
Information provided by:
Cell Genesys

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Primary Completion Date : October 2008
  Study Completion Date : October 2008